Allcyte
Allcyte is a biotech start-up specializing in functional drug testing using primary human material. Their core product is the Pharmacoscopy high-content imaging platform combined with AI-supported image analysis pipelines. This technology enables personalized medicine for cancer patients by quantifying single-cell phenotypes directly from patient samples with minimal manipulation. Allcyte supports pharmaceutical companies by focusing drug development on the right molecules and indications. Their approach integrates advanced statistics and machine learning to provide actionable biomedical insights, aiming to improve treatment decisions and accelerate drug discovery.
Allcyte
Allcyte is a biotech start-up specializing in functional drug testing using primary human material. Their core product is the Pharmacoscopy high-content imaging platform combined with AI-supported image analysis pipelines. This technology enables personalized medicine for cancer patients by quantifying single-cell phenotypes directly from patient samples with minimal manipulation. Allcyte supports pharmaceutical companies by focusing drug development on the right molecules and indications. Their approach integrates advanced statistics and machine learning to provide actionable biomedical insights, aiming to improve treatment decisions and accelerate drug discovery.
TL;DR
Company: Allcyte — Vienna-based biotech focused on pharmacoscopy (image-based, single-cell functional drug testing)
Founded: 2017
Headcount: 77 employees
Core tech: High-content imaging platform (Pharmacoscopy) + AI-supported image analysis
Funding / exit: Seed and grant rounds in 2020; reported acquisition by Exscientia in 2021
Company Overview
Problem Domain
Precision oncology; translational drug development; functional diagnostics using primary human tissue.
Founded
2017
Industry
Biotech / Precision Medicine
Funding Track Record
Seed round reported in July 2020
EIT Health grant announced July 9, 2020
Investor Signal
“Investors reported include EIT Health, Amino Collective, Air Street Capital, PUSH VC, Venture Partners AG, 42CAP; company reported acquired by Exscientia in 2021”